Medtech Maze CEO Paulina Jonasson Foresees Precision Medicine in 2026
Photo by Markus Winkler on Unsplash
Medtech Maze CEO Paulina Jonasson predicts that precision medicine will become predominant in medtech by 2026. This transition is enabled by the successful implementation of regulatorily approved AI solutions in healthcare, projected for 2025, and will be further driven by AI-powered image analysis as well as advanced risk profiling, leading to less reliance on general solutions.
Key takeaways
- In a recent interview with Medtech Magazine, Paulina Jonasson, CEO and partner at Medtech Maze, forecasts a substantial transition towards precision medicine within the medtech industry by 2026
- Jonasson emphasizes that the widespread adoption and implementation of regulatorily approved AI solutions in healthcare during 2025 represent a pivotal achievement for artificial intelligence in clinical settings
- Looking forward, Jonasson anticipates a decline in the reliance on general medical solutions
Related Topics
Want coverage like this for your company?
Local & industry wins build trusted proof, SEO/geo signals and prime national editors.
Check fit (2 min)Is this your company?
Set up real-time alerts and keep your Heartspace News coverage accurate. Verified teams can update profiles, request corrections, and collaborate on future stories.
Want to turn mentions into momentum? Find your best path with the Fit Checker. Verified profiles receive a free consult.